Tirabrutinib Recruiting Phase 2 Trials for Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04947319Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)